Results 181 to 190 of about 4,608 (197)

Thymoma Treated With 177Lu DOTATATE Induction and Maintenance PRRT

Clinical Nuclear Medicine, 2015
A 47-year-old man presented with a recurrent thymoma World Health Organization type A of the anterior chest wall with pleural metastases after failing chemotherapy. The tumor was positive on In-octreotide, and he was referred for peptide receptor radionuclide therapy (PRRT) with Lu DOTATATE.
William, Makis, Karey, McCann, Alexander J B, McEwan   +2 more
openaire   +2 more sources

Liver Steatosis Secondary to PRRT With 177Lu-DOTATATE

Clinical Nuclear Medicine, 2020
Abstract PRRT (peptide receptor radionuclide therapy) with 177Lu-DOTATATE for neuroendocrine tumor has some well-known adverse effects, concerning specially the bone marrow and kidneys. Hepatotoxicity has been rarely reported, and there are no data regarding hepatic steatosis secondary to PRRT. We reviewed upper abdomen CT and MRI and applied
Beatriz Matheos, de Lima, Juliana Ribeiro, de Carvalho, Priscilla Romano, Gaspar, Priscilla Brunelli, Pujatti, Rinaldo, Gonçalves   +4 more
openaire   +2 more sources

Long-term results of PRRT in advanced bronchopulmonary carcinoid

European Journal of Nuclear Medicine and Molecular Imaging, 2015
Peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumours (NET) has been explored for almost two decades, but there are still few trials that have exclusively investigated well-differentiated and moderately differentiated NET arising from the respiratory tree.
Mariniello, Annapaola, Bodei, Lisa, Tinelli, Carmine, Baio, Silvia Melania, Gilardi, Laura, Colandrea, Marzia, Papi, Stefano, Valmadre, Giuseppe, Fazio, Nicola, Galetta, Domenico, PAGANELLI, Giovanni, Grana, Chiara Maria   +11 more
openaire   +2 more sources

Nierenfunktion und Peptid-Rezeptor-Radionuklid-Therapie (PRRT)

Der Nuklearmediziner, 2011
Die Radionuklidrezeptortherapie (PRRT) mit 90-Yttrium oder 177-Lutetium gekoppelten Somatostatinanaloga ist eine der systemischen und antitumorosen Therapieoptionen bei Patienten mit gastroenteropankreatischen, neuroendokrinen Tumoren (GEP-NET). Eine physiologische Anreicherung des Radiopharmazeutikum akkumuliert sich in den Nieren, die somit die ...
openaire   +1 more source

166Holmium-SIRT after PRRT (HEPAR PLuS) versus PRRT-only in Patients with Metastatic Neuroendocrine Tumors: a Propensity-score Matched Analysis

2023
Weitere Verfasser aus Einrichtungen außerhalb der Universität Duisburg-Essen sind nicht ...
Braat, A., Walter, T., de Vries-Huizing, D., Theysohn, Jens, Lahner, Harald   +4 more
openaire   +1 more source

Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT).

Hellenic journal of nuclear medicine, 2016
Neuroendocrine tumors (neuroendocrine tumors-NET) are a heterogeneous group of neoplasms with a common embryological origin and diverse biological behavior, derived from cells of the neuroendocrine system, the system APUD (amine precursor uptake and decarboxylation).
Dimitris G, Papamichail, Paraskevi E, Exadaktylou, Vasiliki D, Chatzipavlidou   +2 more
openaire   +3 more sources

Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren

Der Onkologe, 2004
R. P. Baum, J. S�ldner, M. Schm�cking, A. Niesen   +3 more
openaire   +1 more source

NET: die PRRT ein therapeutischer Standard

Im Fokus Onkologie, 2021
openaire   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT): clinical Application

2015
Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and related symptoms.
Bodei, Lisa, PAGANELLI, Giovanni
openaire   +1 more source

The Cruel Wait for PRRT

Endocrine Abstracts, 2016
openaire   +1 more source